Janar Sathananthan, Ole De Backer, and Michael Reardon dive into the newest findings on TAVR from the late-breaking ACURATE IDE trial.

Though X (formerly Twitter) was once a place many cardiologists found community and opportunity, many are jumping ship.

An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Written to offer advice where formal guidelines fall short, the document urges a balance between bleeding and ischemic risk.